Cubist Systematic Strategies’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Cubist Systematic Strategies’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,707	Closed	-$195K	–	2130
2017 Q2	$195K	Buy	+17,707	New	+$177K	0.01%	1297
2017 Q1	–	Sell	-18,610	Closed	-$201K	–	2017
2016 Q4	$201K	Sell	18,610 -8,702	-32%	-$87K	0.02%	1260
2016 Q3	$280K	Buy	27,312 +13,631	+100%	+$148K	0.02%	1052
2016 Q2	$179K	Buy	+13,681	New	+$179K	0.01%	1372
2015 Q3	–	Sell	-17,336	Closed	-$170K	–	2142
2015 Q2	$170K	Buy	+17,336	New	+$158K	0.01%	1496
2015 Q1	–	Sell	-21,113	Closed	-$185K	–	2205
2014 Q4	$185K	Sell	21,113 -14,575	-41%	-$118K	0.01%	1544
2014 Q3	$246K	Buy	35,688 +3,071	+9%	+$18.4K	0.02%	1234
2014 Q2	$172K	Buy	+32,617	New	+$159K	0.01%	1219

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cubist Systematic Strategies's SCLN Position: Q3 2017 in Review

Cubist Systematic Strategies sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 17,707 shares — an estimated $195K sold.

Cubist Systematic Strategies first reported a position in SCLN in Q2 2014 and held it in 8 quarters. The position peaked at $280K in Q3 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Cubist Systematic Strategies reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Cubist Systematic Strategies sold 17,707 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $195K.
Cubist Systematic Strategies first reported a position in Sciclone Pharmaceuticals Inc in Q2 2014 and held it in 8 quarters.
Cubist Systematic Strategies's Sciclone Pharmaceuticals Inc position peaked at $280K in Q3 2016.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Cubist Systematic Strategies's 13F filing for Q3 2017, filed 14 Nov 2017.